Toggle navigation
Home
Search
Services
Blog
Contact
About
Rational Design of Neuropeptide Y Therapeutics
Salon, John A.
Synaptic Pharmaceutical Corporation, Paramus, NJ, United States
Search 7 grants from John Salon
Search grants from Synaptic Pharmaceutical Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Causal inference in infectious disease prevention studies
Building Capacity of Tobacco Cessation in India &Indonesia
Core - Cytogenetics Core Facility
Immunological Aspects of AIDS-Related Synthetic Peptides
CAREER: Solid State Chemistry of Unusual Zintl Phases and Polar Intermetallics
Recently added grants:
The contribution of perivascular adipose tissue macrophages to microvascular dysfunction in obesity
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosis
Automated Abdominal Binder for Orthostatic Hypotension
Regulation and role of the cardiac sodium channel Nav1.5 in heart failure
Temporal effects of inflammation on the autonomic control of circulation during exercise in type 2 diabetic rats
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44NS031843-03
Application #
2269799
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (13))
Project Start
1994-09-01
Project End
1996-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Synaptic Pharmaceutical Corporation
Department
Type
DUNS #
City
Paramus
State
NJ
Country
United States
Zip Code
07652
Related projects
NIH 1995
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
NIH 1994
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
Comments
Be the first to comment on this grant